Response rates by WHO classification*
. | RA, n = 3 . | RARS, n = 8 . | RCMD, n = 12 . | RCMD/RS, n = 11 . | RAEB-1, n = 11 . | RAEB-2, n = 4 . | 5q-, n = 8 . | Unclassified, n = 4 . |
|---|---|---|---|---|---|---|---|---|
| CR | 2 | 4 | 4 | 1 | 0 | 2 | 2 | 0 |
| PR | 0 | 2 | 2 | 0 | 4 | 0 | 2 | 2 |
| NR | 1 | 2 | 6 | 10 | 8 | 2 | 4 | 2 |
. | RA, n = 3 . | RARS, n = 8 . | RCMD, n = 12 . | RCMD/RS, n = 11 . | RAEB-1, n = 11 . | RAEB-2, n = 4 . | 5q-, n = 8 . | Unclassified, n = 4 . |
|---|---|---|---|---|---|---|---|---|
| CR | 2 | 4 | 4 | 1 | 0 | 2 | 2 | 0 |
| PR | 0 | 2 | 2 | 0 | 4 | 0 | 2 | 2 |
| NR | 1 | 2 | 6 | 10 | 8 | 2 | 4 | 2 |
RARS versus RCMD/RS (CR + PR). P = .003.
For response criteria, see “WHO classification and outcome of GF treatment” and Hellström-Lindberg et al10 and Cheson et al.28,29